Analytical Data
-
Gene name
MCP-2/CCL8
- Application
-
Alternative Names
CCL8; CCL-8; SCYA8; MCP-2; HC14; Chemokine C-C-Motif Ligand 8; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 8; Monocyte Chemoattractant Protein 2
-
Species
Dog
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q68AY9
-
Expression Region
Gln24~Pro99
-
Protein Length
Partial
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MCP-2, also known as CCL8, is a member of the CC chemokine family, playing a crucial role in immune response and inflammation by acting as a chemotactic factor for monocytes, basophils, and lymphocytes. Its significance in various pathological conditions, such as chronic inflammatory diseases, cancer, and autoimmune disorders, has sparked interest in understanding its biological functions and underlying mechanisms. Research has demonstrated that MCP-2/CCL8 is involved in promoting angiogenesis, modulating immune cell trafficking, and influencing cytokine production, which can have pathological implications. The availability of recombinant MCP-2/CCL8 protein allows researchers to investigate its role in various cellular assays and animal models, facilitating the exploration of potential therapeutic strategies targeting MCP-2/CCL8 signaling pathways. These studies aim to elucidate the molecular interactions and pathways influenced by MCP-2/CCL8, providing insights into its contributions to disease progression and highlighting its potential as a therapeutic target. The recombinant protein can also be used in drug discovery efforts to develop molecules that inhibit its action, thus potentially ameliorating diseases associated with its overexpression. Overall, the study of recombinant MCP-2/CCL8 protein is pivotal not only for advancing our understanding of immune regulation but also for developing novel therapeutic approaches for managing inflammation-related disorders.
